13.64

1.87% -0.26

NeuroPace Inc (NPCE)

Overview News Price History Financials Discussions Forecast

NeuroPace Inc stock is currently priced at $13.64, with a 24-hour trading volume of 43,022. It has seen a -1.87% decreased in the last 24 hours and a +10.27% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $13.89 pivot point. If it approaches the $13.51 support level, significant changes may occur.

Previous Close:

$13.90

Open:

$14.19

24h Volume:

43,022

Market Cap:

$391.74M

Revenue:

$65.42M

Net Income/Loss:

$-32.96M

P/E Ratio:

-8.0235

EPS:

-1.7

Net Cash Flow:

$-19.87M

1W Performance:

+1.87%

1M Performance:

+10.27%

6M Performance:

+90.24%

1Y Performance:

+180.66%

1D Range:

$13.57

$14.19

52W Range:

$3.80

$18.15

NeuroPace Inc Stock (NPCE) Company Profile

Name

NeuroPace Inc

Sector

Healthcare (1213)

Industry

Medical Devices (160)

Phone

650-237-2700

Address

455 North Bernardo Avenue, Mountain View

Employee

153

Twitter

Next Earnings Date

2024-05-08

Latest SEC Filings

NPCE's Discussions on Twitter

NeuroPace Inc Stock (NPCE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-24-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-22-23	Initiated	Lake Street	Buy
Apr-06-22	Initiated	Wolfe Research	Outperform
Jan-19-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-07-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-11-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-18-21	Initiated	Robert W. Baird	Outperform
May-17-21	Initiated	JP Morgan	Overweight
May-17-21	Initiated	Morgan Stanley	Overweight
May-17-21	Initiated	SVB Leerink	Outperform
May-17-21	Initiated	Wells Fargo	Overweight

View All

NeuroPace Inc Stock (NPCE) Latest News

NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

GlobeNewswire Inc.

NeuroPace Inc Stock (NPCE) Financials Data

NeuroPace Inc (NPCE) Revenue 2024

NPCE reported a revenue (TTM) of $65.42 million for the quarter ending December 31, 2023, a +43.72% rise year-over-year.

NeuroPace Inc (NPCE) Net Income 2024

NPCE net income (TTM) was -$32.96 million for the quarter ending December 31, 2023, a +30.00% increase year-over-year.

NeuroPace Inc (NPCE) Cash Flow 2024

NPCE recorded a free cash flow (TTM) of -$19.87 million for the quarter ending December 31, 2023, a +46.96% increase year-over-year.

NeuroPace Inc (NPCE) Earnings per Share 2024

NPCE earnings per share (TTM) was -$1.27 for the quarter ending December 31, 2023, a +33.85% growth year-over-year.

NeuroPace Inc Stock (NPCE) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
ORBIMED ADVISORS LLC	10% Owner	May 02 '24	Sale	14.01	8,842	123,876	3,411,009
ORBIMED ADVISORS LLC	10% Owner	May 01 '24	Sale	14.02	15,690	219,974	3,419,851
ORBIMED ADVISORS LLC	10% Owner	Apr 24 '24	Sale	14.06	1,781	25,041	3,435,541
ORBIMED ADVISORS LLC	10% Owner	Apr 23 '24	Sale	14.29	21,791	311,393	3,437,322
ORBIMED ADVISORS LLC	10% Owner	Apr 22 '24	Sale	14.05	24,609	345,756	3,459,113
ORBIMED ADVISORS LLC	10% Owner	Apr 19 '24	Sale	14.02	18,253	255,907	3,483,722
ORBIMED ADVISORS LLC	10% Owner	Apr 18 '24	Sale	14.06	2,623	36,879	3,501,975
ORBIMED ADVISORS LLC	10% Owner	Apr 17 '24	Sale	14.15	300	4,245	3,504,598
ORBIMED ADVISORS LLC	10% Owner	Apr 16 '24	Sale	14.01	14,069	197,107	3,504,898
ORBIMED ADVISORS LLC	10% Owner	Apr 12 '24	Sale	14.42	23,101	333,116	3,518,967

NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.